CAPE administration was shown to prevent oxidative stress and neuroinflammation and reverse cognitive impairment in AβO-injected mice—effects that appeared to be mediated by Nrf2 activation [65]. The gene discussed is NFE2L2; the disease is Cognitive impairment.